Chronic Anemia in MDS: Focus on Newer Strategies for ESA-refractory or Relapsed Patients

Chronic Anemia in MDS: Focus on Newer Strategies for ESA-refractory or Relapsed Patients
Chronic Anemia in MDS: Focus on Newer Strategies for ESA-refractory or Relapsed Patients
CME, CPE
David Sallman, MD
Release Date: April 05, 2021
Expiration Date: April 05, 2022

In this activity, Dr. Sallman will review conventional strategies and explore emerging concepts for managing MDS and chronic anemia in those who have relapsed after or are refractory to erythropoiesis stimulating agents (ESAs). Topics will include the phase 3 COMMAND trial comparing luspatercept versus ESAs as frontline treatment for patients with lower-risk MDS and anemia; the role of lenalidomide with ESAs for non-ring sideroblast MDS and/or del 5q-mutated MDS; the first-in-class telomerase inhibitor imetelstat; treatment targets within the pyroptosis/inflammasome activation pathway; and the data supporting novel hypomethylating agent doublets for frontline care of high-risk MDS, including azacitidine with magrolimab, azacitidine with pevonedistat, and azacitidine with sabatolimab.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc.
Begin, Earn CreditView Only, No Credit